Mitomycin FDA Approval: Bladder Cancer Treatment
The FDA has approved mitomycin intravesical solution (Zusduri) – a groundbreaking treatment for adult patients battling recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This marks a important step forward, offering the first FDA-approved therapy specifically for this cancer type. The ENVISION trial showed extraordinary results: a 78% complete response rate,presenting a nonsurgical choice to transurethral resection of bladder tumor (TURBT). This innovative approach may transform how LG-IR-NMIBC is managed. Discover the new,gel-based solution administered directly into the bladder via a catheter,designed to maximize drug exposure. News Directory 3 delivers the latest updates on this breakthrough, which offers potential for improved patient outcomes and a better quality of life. Explore the implications of this approval, and learn what it means for the future of bladder cancer treatment.
FDA Approves Mitomycin for Non-Muscle Invasive Bladder Cancer
The Food and Drug Administration has given the green light to mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients facing recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This marks the first FDA-approved treatment for this specific type of bladder cancer,according to the agency.
Non-muscle invasive bladder cancer accounts for a large percentage of bladder cancer diagnoses. Intermediate-risk cases, as defined by the International Bladder Cancer Group, involve low-grade tumors that are either multiple, large (over 3 cm), or recurrent within a year. Transurethral resection of bladder tumor (TURBT) has been the standard treatment, but it frequently enough falls short in controlling LG-IR-NMIBC.
Mitomycin intravesical solution, a gel-based formulation, is designed for nonsurgical use. Administered via a urethral catheter, the solution turns into a gel at body temperature, creating a drug reservoir in the bladder for up to six hours. This prolonged contact aims to maximize drug exposure to tumor tissue while limiting absorption into the bloodstream.Studies suggest that extending mitomycin’s contact time in the bladder can reduce recurrence rates.
The ENVISION trial, a multicenter study, involved 240 adults with recurrent LG-IR-NMIBC after TURBT. Patients received weekly instillations of 75 mg of mitomycin intravesical solution for six weeks. The primary goals were to assess the complete response rate at three months and the duration of that response.
Trial data indicated that 78% of patients achieved a complete response, with the duration of response ranging from zero to over 25 months. Moreover, 79% of those who responded maintained that response for at least a year.
The most common side effects included increased creatinine and potassium levels, dysuria, decreased hemoglobin, elevated liver enzymes, increased eosinophils, decreased lymphocytes and neutrophils, urinary tract infection, and hematuria. Serious adverse events occurred in 12% of patients, including urinary retention and urethral stenosis. One patient experienced fatal cardiac failure.
The FDA’s approval offers a new option for patients who have historically relied on TURBT.The availability of an outpatient therapy represents a notable advancement in improving outcomes and quality of life.
“[Mitomycin intravesical solution] marks a breakthrough in uro-oncology, offering a new alternative for recurrent LG-IR-NMIBC patients who can live for many years with the disease but often endure multiple resections, under general anesthesia,” said Dr. Sandip Prasad, director of Genitourinary Surgical Oncology at Morristown Medical Center/Atlantic Health System, NJ, and principal investigator of the ENVISION trial. “For decades, TURBT has been the standard approach for bladder cancer treatment. That’s why innovative treatments like [mitomycin intravesical solution] are essential, especially for those adult patients with recurrent low-grade, intermediate-risk NMIBC.”
What’s next
With this approval, focus will likely shift to real-world implementation and further studies on long-term efficacy and optimal use of mitomycin intravesical solution in treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.